ライフサイエンスコーパス: sulfadoxine

1 d the impact of dhps genotype on response to sulfadoxine.

2 of the antifolate combination pyrimethamine/sulfadoxine.

3 ays) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose); amo

4 ks were randomly assigned in blocks of 16 to sulfadoxine (250 mg) plus pyrimethamine (12.5 mg; n=319

5 dren were treated with either chloroquine or sulfadoxine\#8211;pyrimethamine and followed for 28 days

6 terval [CI], 93 to 100), and the efficacy of sulfadoxine\#8211;pyrimethamine was 21% (95% CI, 13 to 3

7 pared with 71 of 87 participants assigned to sulfadoxine\#8211;pyrimethamine.

8 stions about any policy to use pyrimethamine-sulfadoxine alone as the first-line treatment for malari

9 ard regimens of chloroquine or pyrimethamine-sulfadoxine alone or in combination with 1 or 3 doses of

10 her in the group that received pyrimethamine-sulfadoxine alone.

11 aged 6 months to 5 years to receive 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine plus either pla

12 Tp with sulfadoxine-pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day), month

13 s lowest in those who received pyrimethamine-sulfadoxine and 3 doses of artesunate, and it was 8-fold

14 t HIV(+) women received a dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine.

15 replace chloroquine with the combination of sulfadoxine and pyrimethamine for the treatment of malar

16 The pharmacokinetics of sulfadoxine and pyrimethamine were compared between thes

17 reening, prophylaxis with the combination of sulfadoxine and pyrimethamine, and treatment, as needed.

18 receive sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, and 1.25 mg/kg pyrimethamine) plus placebo;

19 Glu540 of DHPS was selected by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment, sh

20 iants is important for in vivo resistance to sulfadoxine in the area studied.

21 nthetase (DHPS), in the parasite response to sulfadoxine inhibition.

22 loroquine, and the combination pyrimethamine-sulfadoxine is the most commonly chosen alternative.

23 f lumefantrine (n = 279), quinine (n = 104), sulfadoxine (n = 67), artemisinin (n = 28), chloroquine

24 ks after treatment with either pyrimethamine-sulfadoxine or chlorproguanil-dapsone was analyzed for v

25 rve (AUC(0-->infinity)) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum

26 rtum status did have a significant affect on sulfadoxine pharmacokinetics.

27 fects of vitamin A and the antimalarial drug sulfadoxine pyramethamine (SP) on erythropoietin product

28 ria in infants aged 2-11 months, but neither sulfadoxine-pyrimethamine (-6.7%, -45.9 to 22.0) nor chl

29 thamine (44/125 [35%]) than with amodiaquine+sulfadoxine-pyrimethamine (12/129 [9%]; risk difference

30 for retreatment over 28 days for amodiaquine+sulfadoxine-pyrimethamine (17/129 [13%]) and amodiaquine

31 eive: chloroquine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg

32 k (RR) 0.97 [95% CI 0.84-1.12]; p = 0.70) or sulfadoxine-pyrimethamine (30.0% versus 26.4%, RR 1.14 [

33 re was significantly higher with chloroquine+sulfadoxine-pyrimethamine (44/125 [35%]) than with amodi

34 and gravidity, to receive monthly IPTp with sulfadoxine-pyrimethamine (500 mg of sulfadoxine and 25

35 slightly larger antimalarial effect than did sulfadoxine-pyrimethamine (8 g, -9 to 26), although more

36 lorproguanil-dapsone was less effective than sulfadoxine-pyrimethamine (adjusted odds ratio [OR], 6.4

37 Artesunate-sulfadoxine-pyrimethamine (ASSP) is the frontline artemi

38 iving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy.

39 ermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of e

40 ttent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) would improve matern

41 ttent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

42 es on intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP).

43 ntive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

44 ived intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP).

45 mittent preventive therapy in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

46 hree or more (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).

47 % CI 0 to 13) in areas of high resistance to sulfadoxine-pyrimethamine (Lys540Glu >=90% in east and s

48 re enrolled and randomly assigned to receive sulfadoxine-pyrimethamine (n=391) or dihydroartemisinin-

49 3 days of amodiaquine (n=270), amodiaquine +sulfadoxine-pyrimethamine (n=507), or amodiaquine+artesu

50 ), or intermittent preventive treatment with sulfadoxine-pyrimethamine (n=515); 1368 (88%) women comp

51 monthly dihydroartemisinin-piperaquine with sulfadoxine-pyrimethamine (or another compound with non-

52 d with increased risk of clinical failure of sulfadoxine-pyrimethamine (S/P).

53 patients treated with chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus

54 The frequency of molecular markers of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resi

55 afety and efficacy of this drug with that of sulfadoxine-pyrimethamine (SP) as treatment for uncompli

56 t in infants (IPTi) is the administration of sulfadoxine-pyrimethamine (SP) at 2, 3, and 9 months of

57 ntive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malar

58 spectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 t

59 However, sulfadoxine-pyrimethamine (SP) efficacy is threatened by

60 Resistance to the antimalarial drug sulfadoxine-pyrimethamine (SP) emerged in Plasmodium fal

61 d Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventi

62 owever, parasites resistant to the IPTp drug sulfadoxine-pyrimethamine (SP) have emerged worldwide, a

63 rapy against malaria in pregnancy (IPT) with sulfadoxine-pyrimethamine (SP) in Malawi, the impacts of

64 artemisinin-piperaquine (DP) was superior to sulfadoxine-pyrimethamine (SP) in preventing maternal an

65 quine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalari

66 iparum genes Pfdhfr and Pfdhps have rendered sulfadoxine-pyrimethamine (SP) ineffective for malaria t

67 iveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-t

68 ffordable drugs such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) is a major global health

69 Sulfadoxine-pyrimethamine (SP) is among the most commonl

70 ntive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against mal

71 reventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malari

72 Sulfadoxine-pyrimethamine (SP) is used as intermittent p

73 Sulfadoxine-pyrimethamine (SP) is used throughout Africa

74 n used bednets and received a single dose of sulfadoxine-pyrimethamine (SP) on enrollment, followed b

75 Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), gi

76 study of IPTp comparing the standard 2-dose sulfadoxine-pyrimethamine (SP) regimen with monthly IPTp

77 tations associated with chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance and the micros

78 Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan

79 In 2007, Malawi replaced sulfadoxine-pyrimethamine (SP) with an artemisinin-based

80 t 6 mo of age to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfa

81 were treated for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), o

82 revalence of malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recom

83 s included placebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), SP+amodiaquine, SP+piper

84 and is sometimes inadvertently treated with sulfadoxine-pyrimethamine (SP).

85 reventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP).

86 Es) following simultaneous administration of sulfadoxine-pyrimethamine (SP-IPTi) with immunizations,

87 nthly DHA-PQ (120/960 mg DHA/PQ; n = 373) or sulfadoxine-pyrimethamine (SP; 1500/75 mg; n = 375) duri

88 falciparum parasites partially resistant to sulfadoxine-pyrimethamine (with quintuple mutations) pot

89 activity of dihydroartemisinin-piperaquine, sulfadoxine-pyrimethamine alone was associated with impr

90 is reduced in areas with high resistance to sulfadoxine-pyrimethamine among P falciparum parasites,

91 year and location with treatment studies of sulfadoxine-pyrimethamine among symptomatic children.

92 .48 [95 CI 1.04-2.12]; p = 0.03) compared to sulfadoxine-pyrimethamine and a higher risk of preterm d

93 seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) in chi

94 ere is already a high level of resistance to sulfadoxine-pyrimethamine and amodiaquine.

95 area with a high prevalence of resistance to sulfadoxine-pyrimethamine and chloroquine.

96 a double-blind, placebo-controlled trial of sulfadoxine-pyrimethamine and chlorproguanil-dapsone tre

97 ommended antimalarials, such as Chloroquine, Sulfadoxine-Pyrimethamine and oral Artesunate monotherap

98 ttent preventive treatment with two doses of sulfadoxine-pyrimethamine and the use of insecticide-tre

99 ium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days

100 IPTp with sulfadoxine-pyrimethamine appears to have potent non-mal

101 ntly evaluated as a potential alternative to sulfadoxine-pyrimethamine as intermittent preventive tre

102 ial of IPTi in an area of high resistance to sulfadoxine-pyrimethamine at sites of moderate (n=1280 i

103 Administration of sulfadoxine-pyrimethamine at times of vaccination-interm

104 among neonates of women randomly assigned to sulfadoxine-pyrimethamine compared with women assigned t

105 Mediation analyses showed sulfadoxine-pyrimethamine conferred a greater non-malari

106 IPTi with sulfadoxine-pyrimethamine did not have a clinically sign

107 ombining dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine did not reduce the risk of a c

108 INTERPRETATION: IPTi with sulfadoxine-pyrimethamine does not affect serological re

109 Nine trials of IPT with sulfadoxine-pyrimethamine during pregnancy in Africa wer

110 trials compared 2-dose with monthly IPT with sulfadoxine-pyrimethamine during pregnancy.

111 atment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months

112 cy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third tr

113 In areas in which 1 of 4 treatments with sulfadoxine-pyrimethamine fail in children by day 14, th

114 , Uganda, were treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplica

115 e is a promising alternative drug to replace sulfadoxine-pyrimethamine for intermittent preventive tr

116 ombining dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine for IPTp did not improve birth

117 ampala, Uganda were treated with amodiaquine+sulfadoxine-pyrimethamine for uncomplicated malaria.

118 n the intermittent preventive treatment with sulfadoxine-pyrimethamine group (15 [3%] of 457 women vs

119 misinin-piperaquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the t

120 as significantly lower than in the IPTp with sulfadoxine-pyrimethamine group (300 [74%] of 404 partic

121 icantly different from that in the IPTp with sulfadoxine-pyrimethamine group (352 [87%] of 403 partic

122 atic malaria was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 p

123 ntal malaria was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the thre

124 roup (mean change 13 ms [SD 23]) than in the sulfadoxine-pyrimethamine group (mean change 0 ms [SD 23

125 By day 14, only 1 patient in the sulfadoxine-pyrimethamine group had parasites.

126 the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-d

127 1 (33%; mean age 24.9 years [SD 6.1]) to the sulfadoxine-pyrimethamine group, 1561 (33%; mean age 25.

128 having exit interviews (377 in the IPTp with sulfadoxine-pyrimethamine group, 408 in the IPTp with di

129 quine group, 5 of 290 patients (1.7%) in the sulfadoxine-pyrimethamine group, and 27 of 272 patients

130 mpared with 335 (23.3%) of 1435 women in the sulfadoxine-pyrimethamine group, the primary composite e

131 s compared to sulfadoxine-pyrimethamine, but sulfadoxine-pyrimethamine has been associated with impro

132 Sulfadoxine-pyrimethamine has been widely used as first-

133 IPTi with sulfadoxine-pyrimethamine has no benefit in areas of ver

134 vel resistance to the antifolate combination sulfadoxine-pyrimethamine have a common origin.

135 Schools were randomly assigned to treatment (sulfadoxine-pyrimethamine in combination with amodiaquin

136 ve to intermittent preventive treatment with sulfadoxine-pyrimethamine in the context of high sulfado

137 compared the effectiveness of daily CMX with sulfadoxine-pyrimethamine intermittent preventive treatm

138 pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermittent treatment), and t

139 Therapeutic alternatives to sulfadoxine-pyrimethamine IPTp are needed in areas where

140 birthweight (primary outcome) and malaria by sulfadoxine-pyrimethamine IPTp dose, and for studies tha

141 nce in P falciparum and the effectiveness of sulfadoxine-pyrimethamine IPTp for malaria-associated ou

142 The effectiveness of sulfadoxine-pyrimethamine IPTp is reduced in areas with

143 cipant data from 13 surveys (42 394 births), sulfadoxine-pyrimethamine IPTp was associated with reduc

144 asmodium falciparum to the antimalarial drug sulfadoxine-pyrimethamine is a result of extremely rare

145 Increasing resistance to sulfadoxine-pyrimethamine is leading to a decline in its

146 Resistance to sulfadoxine-pyrimethamine is now increasing, especially

147 Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the

148 ent preventive therapy during pregnancy with sulfadoxine-pyrimethamine monotherapy.

149 African country to replace chloroquine with sulfadoxine-pyrimethamine nationwide in response to high

150 Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral ma

151 rmine the effect of increasing resistance to sulfadoxine-pyrimethamine on the efficacy of IPT during

152 Combinations of amodiaquine and sulfadoxine-pyrimethamine or artesunate were significant

153 ytes and asexual parasites more rapidly than sulfadoxine-pyrimethamine or chlorproguanil-dapsone did.

154 We defined treatment as random assignment to sulfadoxine-pyrimethamine or dihydroartemisinin-piperaqu

155 t preventive treatment during pregnancy with sulfadoxine-pyrimethamine or dihydroartemisinin-piperaqu

156 ot improve birth outcomes compared to either sulfadoxine-pyrimethamine or dihydroartemisinin-piperaqu

157 icts that the combination of chloroquine and sulfadoxine-pyrimethamine or fosmidomycin may be more ef

158 We investigated whether IPTi with sulfadoxine-pyrimethamine or other antimalarial drug com

159 o evidence of an adverse effect of IPTi with sulfadoxine-pyrimethamine or other antimalarial drugs on

160 groups (18 and 15, respectively) than in the sulfadoxine-pyrimethamine or placebo groups (eight death

161 ther one dose of artesunate plus one dose of sulfadoxine-pyrimethamine or two placebos on three occas

162 ydroartemisinin-piperaquine (p = 0.0164) and sulfadoxine-pyrimethamine plus amodiaquine (p = 0.0451),

163 mbination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was mo

164 as 63.6% (IQR 0.0-100.0; n=20; p=0.013) with sulfadoxine-pyrimethamine plus amodiaquine and 100% (100

165 seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine and either AZ

166 We evaluated the effectiveness of SMC using sulfadoxine-pyrimethamine plus amodiaquine given over 5

167 uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine plus amodiaquine is used for s

168 the addition of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seas

169 and 100% (100.0-100.0; n=19; p<0.0001) with sulfadoxine-pyrimethamine plus amodiaquine with tafenoqu

170 ither azithromycin or placebo, together with sulfadoxine-pyrimethamine plus amodiaquine, during the a

171 nsiderable post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine; therefore, t

172 zambique using monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively

173 a chemoprevention (SMC) with amodiaquine and sulfadoxine-pyrimethamine provides substantial benefit t

174 We randomly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a

175 l in children by day 14, the 2-dose IPT with sulfadoxine-pyrimethamine regimen continues to provide s

176 loci such as the chloroquine related crt and sulfadoxine-pyrimethamine related dhfr.

177 iation was consistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 96% dihydrop

178 gression to explore the modifying effects of sulfadoxine-pyrimethamine resistance (as indicated by Al

179 valence of molecular markers associated with sulfadoxine-pyrimethamine resistance after three years o

180 adoxine-pyrimethamine in the context of high sulfadoxine-pyrimethamine resistance and malaria transmi

181 Increasing sulfadoxine-pyrimethamine resistance in Africa threatens

182 o assess the associations between markers of sulfadoxine-pyrimethamine resistance in P falciparum and

183 egnant adolescents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread.

184 The effect did not vary by sulfadoxine-pyrimethamine resistance levels (range, 19%-

185 d frequency of parasite mutations conferring sulfadoxine-pyrimethamine resistance might threaten the

186 dication with ACT along with predominance of sulfadoxine-pyrimethamine resistance parasite invoked a

187 , 112 g; 95% CI, 19-205 g) over the range of sulfadoxine-pyrimethamine resistance tested (8%-39%).

188 Sulfadoxine-pyrimethamine resistance was defined as the

189 imates of malaria transmission intensity and sulfadoxine-pyrimethamine resistance, matched by study l

190 eductase Ile164Leu mutation, associated with sulfadoxine-pyrimethamine resistance, was also identifie

191 PTp-DP in settings with different underlying sulfadoxine-pyrimethamine resistance.

192 reas with high malaria transmission and high sulfadoxine-pyrimethamine resistance.

193 y needed, especially for locations with high sulfadoxine-pyrimethamine resistance.

194 tudies that reported on molecular markers of sulfadoxine-pyrimethamine resistance.

195 in Uganda with high malaria transmission and sulfadoxine-pyrimethamine resistance.

196 ern Kenya with high malaria transmission and sulfadoxine-pyrimethamine resistance.

197 We aimed to assess whether sulfadoxine-pyrimethamine shows greater non-malarial ben

198 f the intermittent preventive treatment with sulfadoxine-pyrimethamine strategy recommended by WHO is

199 In a control sulfadoxine-pyrimethamine study, the prevalence of ms476

200 ent kits, which enabled teachers to dispense sulfadoxine-pyrimethamine tablets according to national

201 Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial eff

202 High-level resistance to sulfadoxine-pyrimethamine threatens the efficacy of WHO-

203 Four trials compared 2-dose IPT with sulfadoxine-pyrimethamine to case management or placebo

204 Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during preg

205 mmendation for coadministration of IPTi with sulfadoxine-pyrimethamine to infants at the time of the

206 eatment in pregnancy (IPTp) with single-dose sulfadoxine-pyrimethamine to prevent malaria.

207 the "quintuple mutant") were associated with sulfadoxine-pyrimethamine treatment failure but not with

208 tween the dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine treatment group (54 [16%] of 3

209 gly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and mo

210 uld be included among factors that determine sulfadoxine-pyrimethamine treatment outcome.

211 nfluence of HIV infection on the response to sulfadoxine-pyrimethamine treatment.

212 t preventive therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a higher b

213 ombining dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine was associated with a higher r

214 clinical treatment failure with amodiaquine+sulfadoxine-pyrimethamine was balanced by a lower risk o

215 samples from 2368 children from sites where sulfadoxine-pyrimethamine was compared with placebo were

216 Sulfadoxine-pyrimethamine was first introduced for treat

217 ation associated with clinical resistance to sulfadoxine-pyrimethamine was found in 0.8% of samples f

218 Efficacy of IPT with sulfadoxine-pyrimethamine was lower among women using in

219 01), but dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine was not associated with improv

220 e as a determinant of treatment outcome with sulfadoxine-pyrimethamine was retrospectively studied in

221 Risk of treatment failure with chloroquine+sulfadoxine-pyrimethamine was unacceptably high.

222 Chloroquine and sulfadoxine-pyrimethamine were equivalent in efficacy at

223 d, assessor-blinded clinical trial comparing sulfadoxine-pyrimethamine with mefloquine IPTp.

224 ntimalarial intermittent preventive therapy (sulfadoxine-pyrimethamine) and insecticide-treated mosqu

225 ure to malaria prevention (ITNs or IPTp with sulfadoxine-pyrimethamine) in pregnancy and birth outcom

226 eaving 1904 individuals (934 placebo and 970 sulfadoxine-pyrimethamine) in the study.

227 % (95% CI, 21.1%-32.1%) for amodiaquine plus sulfadoxine-pyrimethamine, 17.4% (95% CI, 13.1%-23.1%) f

228 12 (0.2%) of 6685 sulfadoxine-pyrimethamine, 19 (0.3%) of 7014 dihydroarte

229 amodiaquine, 97 of 476 (20%) for amodiaquine+sulfadoxine-pyrimethamine, 54 of 491 (11%) for amodiaqui

230 of 3 combination therapies (amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate,

231 We compared chloroquine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrim

232 quine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, and amodiaquine+artesunate fo

233 ized controlled trial comparing chloroquine, sulfadoxine-pyrimethamine, and chlorproguanil-dapsone fo

234 in-piperaquine than among those who received sulfadoxine-pyrimethamine, and monthly treatment with di

235 , and categories of resistance: chloroquine, sulfadoxine-pyrimethamine, artemisinin, and piperaquine.

236 wn superior antimalarial effects compared to sulfadoxine-pyrimethamine, but sulfadoxine-pyrimethamine

237 During pregnancy, compared to sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquin

238 sion intensity with widespread resistance to sulfadoxine-pyrimethamine, findings may not be generaliz

239 with intermittent preventive treatment with sulfadoxine-pyrimethamine, intermittent preventive treat

240 Compared with monthly doses of sulfadoxine-pyrimethamine, monthly doses of dihydroartem

241 However, with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed.

242 Intermittent treatment with sulfadoxine-pyrimethamine, recommended for prevention of

243 sinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-pip

244 Compared with three doses of sulfadoxine-pyrimethamine, three doses of dihydroartemis

245 Additionally, sulfadoxine-pyrimethamine-associated mutations show high

246 Molecular assays for monitoring sulfadoxine-pyrimethamine-resistant Plasmodium falciparu

247 nown to confer resistance to chloroquine and sulfadoxine-pyrimethamine.

248 after artesunate-amodiaquine or amodiaquine-sulfadoxine-pyrimethamine.

249 lying decreased efficacy of amodiaquine plus sulfadoxine-pyrimethamine.

250 imalarials such as chloroquine, quinine, and sulfadoxine-pyrimethamine.

251 larial benefits for birth outcomes than does sulfadoxine-pyrimethamine.

252 rapid deterioration of the effectiveness of sulfadoxine-pyrimethamine.

253 artemisinin-piperaquine as an alternative to sulfadoxine-pyrimethamine.

254 improvements in birth outcomes compared with sulfadoxine-pyrimethamine.

255 isinin combination therapy, chloroquine, and sulfadoxine-pyrimethamine.

256 e, or intermittent preventive treatment with sulfadoxine-pyrimethamine.

257 ose); amodiaquine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine; or amodiaquine and artesunate

258 y 54% (95% CI 36-66, p<0.0001) compared with sulfadoxine/ pyrimethamine alone and by 37% (12-54, p=0.

259 eria occurred in 13 of 131 (10%) patients on sulfadoxine/ pyrimethamine, nine of 131 (7%) on amodiaqu

260 a, Uganda, were randomly assigned to receive sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, and 1.2

261 Sulfadoxine/pyrimethamine (Fansidar) is widely used in A

262 between specific alleles and the failure of sulfadoxine/pyrimethamine (S/P) to clear the erythrocyti

263 n a thick film of blood and was treated with sulfadoxine/pyrimethamine (SP), in accordance with natio

264 hamine was significantly more effective than sulfadoxine/pyrimethamine alone in children aged younger

265 Affordable alternative treatments include sulfadoxine/pyrimethamine and amodiaquine.

266 Treatment of malaria with sulfadoxine/pyrimethamine and of presumed bacterial infe

267 rimethamine, amodiaquine, and an amodiaquine/sulfadoxine/pyrimethamine combination for treatment of u

268 The amodiaquine/sulfadoxine/pyrimethamine combination was the most effec

269 days was significantly more frequent in the sulfadoxine/pyrimethamine group (38 of 215, 18%) compare

270 Sulfadoxine/pyrimethamine plus amodiaquine could be used

271 up (38 of 215, 18%) compared with either the sulfadoxine/pyrimethamine plus amodiaquine group (two of

272 After 28 and 42 days, patients in the sulfadoxine/pyrimethamine plus amodiaquine group were si

273 Overall, sulfadoxine/pyrimethamine plus amodiaquine reduced the r

274 diaquine group (two of 164, 1%; p<0.0001) or sulfadoxine/pyrimethamine plus artesunate group (one of

275 ne and by 37% (12-54, p=0.007) compared with sulfadoxine/pyrimethamine plus artesunate.

276 Expanding use of sulfadoxine/pyrimethamine to treat chloroquine-resistant

277 Amodiaquine/sulfadoxine/pyrimethamine was significantly more effecti

278 /pyrimethamine, amodiaquine, and amodiaquine/sulfadoxine/pyrimethamine were all effective for treatme

279 Sulfadoxine/pyrimethamine, amodiaquine, and amodiaquine/

280 We compared the efficacy of sulfadoxine/pyrimethamine, amodiaquine, and an amodiaqui

281 Children <5 years old treated with sulfadoxine/pyrimethamine, cotrimoxazole, or no antimicr

282 ly Proguanil (the standard of care), monthly sulfadoxine/pyrimethamine-amodiaquine (SP-AQ), or monthl

283 In sulfadoxine/pyrimethamine-treated children, the proporti

284 iaquine, and four of 138 (3%) on amodiaquine/sulfadoxine/pyrimethamine.

285 (25 mg/kg) plus placebo; or amodiaquine plus sulfadoxine/pyrimethamine.

286 540 correlated with increased pyrimethamine-sulfadoxine resistance (P < .05).

287 teroate synthase gene (dhps) associated with sulfadoxine resistance and 5 microsatellite loci flankin

288 were common in Bolivia, where pyrimethamine-sulfadoxine resistance is widespread, but absent in Afri

289 esistance) preceded that of the dhps allele (sulfadoxine resistance).

290 e synthase (DHPS) and clinical pyrimethamine-sulfadoxine resistance, polymerase chain reaction survey

291 cular surveillance methods for pyrimethamine-sulfadoxine resistance.

292 spectively associated with pyrimethamine and sulfadoxine resistance.

293 e a watershed for haplotypes associated with sulfadoxine resistance.

294 ries with increasing levels of pyrimethamine-sulfadoxine resistance: Mali, Kenya, Malawi, and Bolivia

295 oyed to identify a clear correlation between sulfadoxine-resistance levels and the number of DHPS mut

296 ross between sulfadoxine-sensitive (HB3) and sulfadoxine-resistant (Dd2) parents.

297 DHPS) confer resistance to pyrimethamine and sulfadoxine, respectively.

298 in the 16 progeny of a genetic cross between sulfadoxine-sensitive (HB3) and sulfadoxine-resistant (D

299 nts to replace chloroquine and pyrimethamine/sulfadoxine threatens efforts to control the spread of d

300 ng prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed